BioWorld

Dec. 7, 2015

View Archived Issues

FDA advisory committees on the decline, results vary

It's been three years since the FDA Safety and Innovation Act, the most recent reauthorization of the user fee program, was enacted, providing plenty of data on advisory committee meetings to examine. Read More

Week in review

Read More

Word on the street

Read More

Week in Washington

Read More

Public financing of biotechnology companies: Commenced trading in November 2015

Read More

Biotech money raised by month in 2015

Read More

Public financing of biotechnology companies: Filed and pending IPOs

Read More

2015 top private financings of public companies

Read More

Other financings of public biotechnology companies: November 2015

Read More

2015 top financings of private companies

Read More

Venture capital & other investments in private biotechnology companies: November 2015

Read More

Milestone payments from corporate partners: November 2015

Read More

Money raised by biotech in 2015 vs. 2014

Read More

Money raised by biotech: Jan. 1 - Dec. 3, 2015

Read More

Nasdaq Stock Index 2015

Read More

The week's biggest gainers and losers

Read More

BioWorld Stock Index 2015

Read More

BioWorld stock report for public biotechnology companies

Read More